We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

By LabMedica International staff writers
Posted on 31 Jul 2014
Print article
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).
A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose metabolism.

Investigators at the Salk Institute for Biological Studies (La Jolla, CA, USA) worked with a mouse model of diet-induced diabetes, the rodent equivalent of human type II diabetes. Previous studies had shown that when these mice were prevented from producing FGF1 and then placed on a high-fat diet, they quickly developed diabetes.

In the current study, the investigators expanded research on the link between FGF1 and diabetes by greatly increasing FGF1 levels in the mice. This was done by injecting the animals with one or more doses of recombinant FGF1 (rFGF1).

Results published in the July 16, 2014, online edition of the journal Nature revealed that the single dose of rFGF1 caused potent, insulin-dependent lowering of glucose levels in diabetic mice that was dose-dependent but did not lead to hypoglycemia. Chronic pharmacological treatment with rFGF1 increased insulin-dependent glucose uptake in skeletal muscle and suppressed production of glucose in the liver to achieve whole-body insulin sensitization. The sustained glucose lowering and insulin sensitization attributed to rFGF1 were not accompanied by the side effects of weight gain, fat accumulation in the liver, and bone loss associated with current insulin-sensitizing therapies. In addition, the glucose-lowering activity of FGF1 could be dissociated from its mitogenic activity and was mediated predominantly via FGF receptor 1 signaling.

"There are many questions that emerge from this work and the avenues for investigating FGF1 in diabetes and metabolism are now wide open," said senior author Dr. Ronald M. Evans, director of the gene expression laboratory at the Salk Institute for Biological Studies. "We want to move this to people by developing a new generation of FGF1 variants that solely affect glucose and not cell growth. If we can find the perfect variation, I think we will have on our hands a very new, very effective tool for glucose control."

Related Links:

Salk Institute for Biological Studies


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.